Linaclotide in patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC)

Trial Profile

Linaclotide in patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC)

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Linaclotide (Primary)
  • Indications Constipation; Irritable bowel syndrome
  • Focus Therapeutic Use
  • Acronyms CONTOR
  • Most Recent Events

    • 16 Oct 2017 According to an Ironwood Pharmaceuticals media release, results from this trial were presented at the World Congress of Gastroenterology (WCOG) at the American College of Gastroenterology (ACG).
    • 12 Oct 2017 Results assessing linaclotide treatment success based on patient-reported survey data on treatment satisfaction, over 6 months, from the chronic constipation and IBS-C treatment, were presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 24 May 2017 Results comparing characteristics of patients from this study and four other linaclotide Phase III RCTs (n=4927), presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top